Last reviewed · How we verify
Favipiravir + Hydroxychloroquine
Favipiravir inhibits viral RNA polymerase while hydroxychloroquine modulates immune response and has antiviral properties, together targeting viral replication and host inflammatory pathways.
Favipiravir inhibits viral RNA polymerase while hydroxychloroquine modulates immune response and has antiviral properties, together targeting viral replication and host inflammatory pathways. Used for COVID-19 (Phase 3 evaluation), Viral respiratory infections.
At a glance
| Generic name | Favipiravir + Hydroxychloroquine |
|---|---|
| Also known as | Favicovir Film Tablet + Hydroxychloroquine sulfate |
| Sponsor | Health Institutes of Turkey |
| Drug class | Antiviral combination (nucleoside analog + immunomodulator) |
| Target | Viral RNA-dependent RNA polymerase (favipiravir); toll-like receptors and endosomal pathways (hydroxychloroquine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Favipiravir is a nucleoside analog that selectively inhibits viral RNA-dependent RNA polymerase, preventing viral genome replication. Hydroxychloroquine is an immunomodulator that increases endosomal pH, inhibits toll-like receptor signaling, and has direct antiviral activity. The combination aims to suppress both viral replication and excessive inflammatory responses.
Approved indications
- COVID-19 (Phase 3 evaluation)
- Viral respiratory infections
Common side effects
- Hyperuricemia
- Gastrointestinal disturbances
- Retinopathy (hydroxychloroquine)
- QT prolongation
- Headache
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients (PHASE4)
- Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 (PHASE3)
- Favipiravir vs Hydroxychloroquine vs Control in COVID -19 (PHASE2)
- Fight COVID-19 Trial (PHASE3)
- FAvipiravir and HydroxyChloroquine Combination Therapy (NA)
- Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment (PHASE3)
- Musculoskeletal Symptoms in Post Acute Covid-19 Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |